Anti-SARS-CoV-2 Recombinant Therapeutic Antibodies

Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: 27
Format: PDF
Product Line: Competitor Analysis
Product Code: LMCA0184
Release Date: August of 2020

Anti-SARS-CoV-2 Recombinant Therapeutic Antibodies

This Competitive Intelligence report about Anti-SARS-CoV-2 Recombinant Therapeutic Antibodies describes the landscape of industry-driven approaches to discover and develop recombinant therapeutic antibodies against SARS-CoV-2 for treatment of COVID-19 as of August 28, 2020.

COVID-19 is caused by SARS-CoV-2, which belongs to a group of viruses called coronaviruses that attack the respiratory system. There is currently no licensed vaccine, treatment or cure for COVID-19. Since the outbreak of the SARS-CoV-2 pandemia, industry efforts rapidly have initiated work to repurpose existing biologic therapeutics and discover and develop novel antibody and protein candidates to treat COVID-19.

As of end of August of 2020, seven novel recombinant therapeutic monoclonal antibodies or antibody cocktails are in clinical development and further at least nine antibody-products are expected to enter clinical development, including recombinant polyclonal antibody preparations.

This report includes a compilation of industry-driven projects in research and development of SARS-CoV-2 targeted recombinant therapeutic antibodies for treatment of COVID-19. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.


Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01